Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,113 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,113 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $46,824.08. Following the completion of the transaction, the chief accounting officer directly owned 22,874 shares in the company, valued at approximately $506,887.84. This trade represents a 8.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Alexander Azoy also recently made the following trade(s):

• On Thursday, December 18th, Alexander Azoy sold 4,343 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.25, for a total value of $96,631.75.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total value of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total value of $36,803.00.

Arcus Biosciences Stock Down 1.2%

NYSE:RCUS traded down $0.26 during mid-day trading on Thursday, reaching $22.02. The company’s stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $26.40. The stock has a fifty day moving average of $20.82 and a 200-day moving average of $13.98. The firm has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the previous year, the business posted ($1.00) EPS. The company’s quarterly revenue was down 45.8% compared to the same quarter last year. Equities research analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. Goldman Sachs Group Inc. increased its holdings in shares of Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after purchasing an additional 470,755 shares during the period. Geode Capital Management LLC boosted its position in Arcus Biosciences by 14.9% in the second quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after buying an additional 207,097 shares during the last quarter. Rhumbline Advisers boosted its position in Arcus Biosciences by 14.8% in the first quarter. Rhumbline Advisers now owns 182,909 shares of the company’s stock valued at $1,436,000 after buying an additional 23,645 shares during the last quarter. Tema Etfs LLC increased its holdings in Arcus Biosciences by 291.2% in the 2nd quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock worth $486,000 after buying an additional 44,411 shares during the period. Finally, Woodline Partners LP raised its position in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after buying an additional 1,603,367 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RCUS. Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. HC Wainwright raised their price objective on Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Truist Financial set a $30.00 target price on shares of Arcus Biosciences in a report on Friday, December 12th. Finally, Bank of America increased their price target on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.